Nuevocor Founders to Present at the American Society of Gene and Cell Therapy (ASGCT) 2022 Meeting

Nuevocor, a pre-clinical stage cardiac gene therapy company, announced that it will present preclinical data on its adeno-associated virus (AAV) gene therapy for LMNA dilated cardiomyopathy at the American Society of Gene and Cell Therapy (ASGCT) meeting earlier this year.

​

Mutations in the LMNA gene, encoding lamin A/C, are thought to be the 2nd most frequent cause of familial dilated cardiomyopathy, affecting approximately 60,000 people in the US and EU alone. Being an autosomal dominant disease characterized by gain-of-function of the mutant lamin A/C protein, conventional gene replacement therapies would be ineffective for LMNA DCM. Nuevocor's unique strategy for treating LMNA DCM instead targets a disease modifier, using AAV to overexpress a transgene that disrupts the Linker of Nucleoskeleton and Cytoskeleton complex to suppress the pathology of LMNA mutations.

Details of the presentation are as follows:

MONDAY, MAY 16 2022

CARDIOVASCULAR AND PULMONARY DISEASES, ROOM 206​

11:30 AM – 11:45 AM​

AAV9-cTnT-GSLA01 Treats LMNA Dilated Cardiomyopathy in a Lmna Mouse Model Following a Decline in Ejection Fraction​

Yin Loon Lee, PhD. Nuevocor

​

MONDAY, MAY 16 2022

STARTUP SHOWCASE, ROOM 209​

12:20 PM – 12:30 PM​

Nuevocor - Leveraging mechanobiology to treat genetic cardiomyopathies​

Yann Chong Tan, PhD. Nuevocor, Singapore